Patent · US Expired

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

US6524347B1 · kind B1 · utility

186Cited by
14References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 29, 2000
Grant dateFeb 25, 2003
Priority date
Expiry dateSep 29, 2020

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D405/12
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.